Navigation Links
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma

nalidomide)/dexamethasone treatment group underwent at least one additional dose interruption with or without a dose reduction compared to 21% in the placebo/dexamethasone treatment group.

Other adverse events reported in multiple myeloma patients (REVLIMID(R) (lenalidomide)/dexamethasone vs dexamethasone/placebo): constipation (39% vs 19%), fatigue (38% vs 37%), insomnia (32% vs 37%), muscle cramp (30% vs 21%), diarrhea (29% vs 25%), neutropenia (28% vs 5%), anemia (24% vs 17%), asthenia (23% vs 25%), pyrexia (23% vs 19%), nausea (22% vs 19%), headache (21% vs 21%), peripheral edema (21% vs 19%), dizziness (21% vs 15%), dyspnea (20% vs 15%), tremor (20% vs 7%), decreased weight (18% vs 14%), thrombocytopenia (17% vs 10%), rash (16% vs 8%), back pain (15% vs 14%), hyperglycemia (15% vs 14%), and muscle weakness (15% vs 15%).

Myelodysplastic Syndromes:

Other adverse reactions reported in del 5q MDS patients (REVLIMID(R)): diarrhea (49%), pruritus (42%), rash (36%), fatigue (31%), constipation (24%), nausea (24%), nasopharyngitis (23%), arthralgia (22%), pyrexia (21%), back pain (21%), peripheral edema (20%), cough (20%), dizziness (20%), headache (20%), muscle cramp (18%), dyspnea (17%), and pharyngitis (16%).

DOSAGE AND ADMINISTRATION:

Dosing is continued or modified based upon clinical and laboratory findings. Dosing modifications are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to lenalidomide. For other Grade 3 or 4 toxicities judged to be related to lenalidomide, hold treatment and restart at next lower dose level when toxicity has resolved to less than or equal to Grade 2.

About REVLIMID(R)

REVLIMID is an IMiDs(R) compound, a member of a proprietary group of novel immunomodulatory agents. REVLIMID and other IMiDs compounds continue to be evaluated in over 75 clinical trials in a broad range of oncological conditions, both in blood cancers a
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood instrumentation and consumables to the medical, research ... , Chairman and Chief Executive Officer, will present at ... Conference 2014 on Tuesday, September 9, 2014 at 12:30 ... Omni Berkshire Place Hotel in New York ...
(Date:8/29/2014)... Columbia and MENLO PARK, Calif. ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") ... year-end financial statements.  The Company recently changed its fiscal ... an application to list its common stock on a ... DelMar,s financial statements as filed with the United ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Orthopedic Soft Tissue Repair Devices Market 2014-2018" ... tissues are the mass of cells that connect, support, ... soft tissues such as tendons, ligaments, cartilage, fascia, and ... degeneration of these tissues with age result in wear ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... (NASDAQ: STAA ), a leading developer, manufacturer and ... its presentation time at the 13 th Annual B. ... be on Wednesday, May 23, 2012 now ... Caldwell, President and CEO, will review the company,s recent financial ...
... 2012  Savvy vice presidents and directors across all ... organizational structures, critical activities, proven processes, and investment ... "In today,s increasingly competitive health ... have analysis from across the worldwide marketplace," says ...
Cached Medicine Technology:B. Riley Revises Timing of STAAR Surgical Presentation at Investor Conference 2Pharmaceutical Commercial Leaders Seek Global Benchmarks for More Informed Decision-Making 2
(Date:8/29/2014)... Daily Gossip reveals in its Stop Sciatica in 8 Minutes ... curing this disease. , The program promises to be ... only one week. This is described as a unique way ... , Moreover, with this new method patients might be ... just 8 minutes. , Interested customers can check the ...
(Date:8/29/2014)... The new review that can be read on DailyGossip.org ... that will permanently eliminate the symptoms of this disease. , ... a cure in as fast as 30 to 60 days. ... one week. , The Tinnitus Miracle review indicates that ... hearing loss, pain in the ear and dizziness. Read the ...
(Date:8/29/2014)... August 29, 2014 Cosmetic Town ... industry’s most notable plastic surgeons with prospective patients. ... about cutting edge techniques in plastic and reconstructive ... contain the most reliable information for general readers, ... treatment.     , Cosmetic Town began featuring renowned cosmetic ...
(Date:8/29/2014)... August 29, 2014 The Nasal ... reveals that the new program is actually based ... method was created by a former nasal polyps ... overcome the disturbing problem. Manuel Richards suffered from ... this system. , Learn more about Manuel ...
(Date:8/29/2014)... FL (PRWEB) August 29, 2014 The ... anxiously awaited final rule (file code CMS–0052–P) today allowing ... using the 2011 Edition Certified EHR Technology (CEHRT) or ... Eligible Professionals (EPs) who have not been able to ... reporting period in 2014 can continue to use 2011 ...
Breaking Medicine News(10 mins):Health News:Stop Sciatica in 8 Minutes Review Exposes Steven Guo's Complete Sciatica Cure 2Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:Cosmetic Town Is Now Connecting Patients with Qualified Cosmetic Specialists 2Health News:Nasal Polyps Treatment Miracle Review Exposes New Natural and Permanent Healing Program 2Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2
... , WASHINGTON , Jan. 13 Bradley C. ... A. Mrusek , a resident of Maineville, Ohio , pleaded guilty late ... R. Barrett in Cincinnati , the Justice Department and Internal Revenue ... wer e i n d icted ...
... is the key, say researchers working with mice , ... giving scientists a greater understanding of how a brain ... level and why some people are resistant to antidepressants. ... stressful life events -- cause the mental disorders. Antidepressants ...
... complete agenda for the Seventh International Chronic ... online at http://www.ctosummit.org/overview/agenda.html . The CTO ... technologies, research findings and new developments in ... optimize success in chronic total coronary occlusions. ...
... , ... and BioScience Laboratories, Inc. announced a formal partnership to provide fully integrated topical clinical ... a single source for outsourcing clinical trials. , ... Wareham, MA (PRWEB) January 13, 2010 -- Synomics Pharma ...
... ... Hepregen’s Previous NIH Funding and Continued Development of the Company’s Platform for Advanced Toxicity ... ... Corporation, a leading provider of bioengineered solutions for drug development, announced today that it ...
... N.H. , Jan. 13 Eleme Medical Inc., ... announced today that they will be conducting a global contest ... of SmoothShapes . An alternative to celebrity endorsement, the campaign,s ... real women who experienced SmoothShapes cellulite and BodySlimming™ treatments, letting ...
Cached Medicine News:Health News:Two Cincinnati Dentists Plead Guilty to Conspiracy, Tax Evasion on Eve of Trial 2Health News:Chronic total occlusion strategies will be discussed during national summit February 4-5 2Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 2Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 3Health News:Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMed Forum 2Health News:Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMed Forum 3Health News:Eleme Medical Announces The Real Women of SmoothShapes(R) Campaign 2Health News:Eleme Medical Announces The Real Women of SmoothShapes(R) Campaign 3
... system facilitates bedside labeling of all ... bank and nursing personnel where the ... The combination admitting ID band and ... patient identification system in facilities where ...
... Location Receiver is an optional component ... to outdoor and difficult environments. AeroScout ... location measurement capabilities packaged in small, ... harsh conditions. The Location Receiver receives ...
Integrate RFID and bar code technology with the new DR1000 Dual RFID/Bar Code Reader by Precision Dynamics Corporation (PDC). It provides an easy migration from bar codes to RFID tags for healthcare ...
... SATO RFID printer reads, writes and prints ... visual image, text or barcode on the ... are ideal for a range of applications, ... Asset Tracking, Baggage Tagging, Retail Labeling, Product ...
Medicine Products: